These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16088168)

  • 1. Long-term remission after 1 course of 12 weeks of alefacept therapy--a case report.
    Vitéz L; Heese E; Wozel G
    Dermatology; 2005; 211(2):165-6. PubMed ID: 16088168
    [No Abstract]   [Full Text] [Related]  

  • 2. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts and review of alefacept in the treatment of psoriasis.
    Krueger GG
    Dermatol Clin; 2004 Oct; 22(4):407-26, viii. PubMed ID: 15450337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remittive effects of intramuscular alefacept in psoriasis.
    Gordon KB; Langley RG
    J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alefacept modifies long-term disease severity and improves the response to other treatments.
    van Duijnhoven MW; de Jong EM; Gerritsen WJ; Pasch MC; van de Kerkhof PC
    Eur J Dermatol; 2005; 15(5):366-73. PubMed ID: 16172047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
    Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
    J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy outcomes in patients using alefacept in the AWARE study.
    Landells I; Searles G; Bissonnette R; Shear NH; Vender R; Lui H
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S122-30. PubMed ID: 20053324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis.
    Prossick TA; Belsito DV
    Cutis; 2006 Sep; 78(3):178-80. PubMed ID: 17036660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; de Jong EM; van de Kerkhof PC
    Acta Derm Venereol; 2006; 86(3):281-2. PubMed ID: 16710605
    [No Abstract]   [Full Text] [Related]  

  • 13. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
    Strober BE; Menon K; McMichael A; Hordinsky M; Krueger G; Panko J; Siu K; Lustgarten JL; Ross EK; Shapiro J
    Arch Dermatol; 2009 Nov; 145(11):1262-6. PubMed ID: 19917955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
    Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
    J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept (Amevive) for treatment of psoriasis.
    Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F; Borenstein M; Kirsner R; Kerdel F
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AWARE study: methodology and baseline characteristics.
    Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on alefacept safety.
    Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.